



## Renalytix to Report First Quarter Fiscal Year 2022 Financial Results on December 7

December 2, 2021

NEW YORK and SALT LAKE CITY, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release first quarter fiscal year 2022 financial results on Tuesday, December 7, 2021, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (EST) / 1:30 p.m. (GMT).

### Conference Call Details:

US/Canada Participant Toll-Free Dial-In Number: (833) 614-1551  
US/Canada Participant International Dial-In Number: (914) 987-7290  
United Kingdom International Dial-In Number: 0800 0288 438  
United Kingdom Local Dial-In Number: 0203 1070 289  
Conference ID: 2495524

**Webcast Registration link:** <https://edge.media-server.com/mmc/p/2s8cwr7x>

**For further information, please contact:**

### Renalytix plc

James McCullough, CEO

[www.renalytix.com](http://www.renalytix.com)

Via Walbrook PR

### Stifel (Nominated Adviser, Joint Broker)

Alex Price / Nicholas Moore

Tel: 020 7710 7600

### Investec Bank plc (Joint Broker)

Gary Clarence / Daniel Adams

Tel: 020 7597 4000

### Walbrook PR Limited

Paul McManus / Lianne Cawthorne

Tel: 020 7933 8780 or [renalytix@walbrookpr.com](mailto:renalytix@walbrookpr.com)

Mob: 07980 541 893 / 07584 391 303

### CapComm Partners

Peter DeNardo

Tel: 415-389-6400 or [investors@renalytix.com](mailto:investors@renalytix.com)

### About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit [www.kidneyintelx.com](http://www.kidneyintelx.com)). For more information, visit [www.renalytix.com](http://www.renalytix.com).